Management of Pulseless Electrical Activity Arrest

Rationale for Not Using Amiodarone in PEA

• Amiodarone is specifically indicated for ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) that is unresponsive to CPR, defibrillation, and vasopressor therapy 4, 5
• The American Heart Association (AHA) guidelines clearly state that amiodarone should be considered only for VF or pulseless VT, not for PEA or asystole 1, 5
• There is no evidence supporting the use of any antiarrhythmic drugs, including amiodarone, for PEA arrest 6

Appropriate Management of PEA Arrest

• High-quality CPR with minimal interruptions (push hard at 100-120/min with complete chest recoil) should be performed 5, 7
• Vasopressor administration (epinephrine 1 mg IV/IO every 3-5 minutes) is recommended 8, 9
• Identifying and treating potential reversible causes (the "H's and T's") is crucial 5

Evidence on Antiarrhythmic Use in Cardiac Arrest

• Clinical trials demonstrating benefit of amiodarone were specifically conducted in patients with refractory VF/pVT, not PEA 1
• The 2010 AHA guidelines state: "Amiodarone may be considered for VF or pulseless VT unresponsive to CPR, defibrillation, and a vasopressor therapy" with no mention of use in PEA 9
• No antiarrhythmic drug given during cardiac arrest has been shown to increase survival to hospital discharge 6, 10

Summary of Recommendations

• For PEA arrest: Focus on high-quality CPR, epinephrine administration, and identifying/treating reversible causes 8, 7
• For VF/pVT arrest: Consider amiodarone 300 mg IV/IO after unsuccessful defibrillation attempts and epinephrine administration 1, 9
• If initially in PEA but rhythm changes to VF/pVT during resuscitation, then amiodarone may be considered at that point 5